MedTrace Logo

A Phase II Study of AS1411 in Renal Cell Carcinoma

NCT00740441 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-09-25

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

AS1411

AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles

Sponsors & Collaborators

  • Antisoma Research

    lead INDUSTRY

Principal Investigators

  • Greg Smith, MD · Saint Francis Hospital

  • Harry Drabkin, MD · Medical University of South Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-09-30
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00740441 on ClinicalTrials.gov